Exact Mass: 652.3723

Exact Mass Matches: 652.3723

Found 58 metabolites which its exact mass value is equals to given mass value 652.3723, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

n-[2(r)-Hydroxy-1(s)-indanyl]-2(r)-phenylmethyl-4(s)-hydroxy-5-[4-[2-benzofuranylmethyl]-2(s)-[tert-butylaminocarbonyl]-piperazinyl]-pentaneamide

4-[(1-Benzofuran-2-yl)methyl]-1-{4-benzyl-2-hydroxy-4-[(2-hydroxy-2,3-dihydro-1H-inden-1-yl)-C-hydroxycarbonimidoyl]butyl}-N-tert-butylpiperazine-2-carboximidate

C39H48N4O5 (652.3625)


   

PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

[(2R)-3-(decanoyloxy)-2-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

[(2R)-3-(decanoyloxy)-2-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

[(2R)-3-(decanoyloxy)-2-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

[(2R)-3-(decanoyloxy)-2-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

[(2R)-3-(decanoyloxy)-2-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.374)


PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Longithorol B

Longithorol B

C42H52O6 (652.3764)


   

12??,21-Dihydroxycimigenol 3-O-??-L-arabinopyranoside

12??,21-Dihydroxycimigenol 3-O-??-L-arabinopyranoside

C35H56O11 (652.3822)


   

(3beta,6beta,12beta,23S,24R,25S)-16,23:23,26-diepoxy-6,12,24,25-tetrahydroxy-9,19-cycloart-3-O-beta-D-xylopyranoside|yunnanterpene F

(3beta,6beta,12beta,23S,24R,25S)-16,23:23,26-diepoxy-6,12,24,25-tetrahydroxy-9,19-cycloart-3-O-beta-D-xylopyranoside|yunnanterpene F

C35H56O11 (652.3822)


   

paradrymonoside

paradrymonoside

C35H56O11 (652.3822)


   

1beta,2alpha,3beta,19alpha,23-pentahydroxyurs-12-en-28-oic acid-28-O-beta-D-xylopyranoside

1beta,2alpha,3beta,19alpha,23-pentahydroxyurs-12-en-28-oic acid-28-O-beta-D-xylopyranoside

C35H56O11 (652.3822)


   

Glu Ile Arg His Val

Glu Ile Arg His Val

C28H48N10O8 (652.3656)


   

Lys Leu Asn His Gln

Lys Leu Asn His Gln

C28H48N10O8 (652.3656)


   

EIRHV

Glu-Ile-Arg-His-Val

C28H48N10O8 (652.3656)


   

N,N-DI-P-TOLYL-N,N-BIS-(4-BUTYLPHENYL)-PHENANTHRENE-9,10-DIAMINE

N,N-DI-P-TOLYL-N,N-BIS-(4-BUTYLPHENYL)-PHENANTHRENE-9,10-DIAMINE

C48H48N2 (652.3817)


   

(2S)-4-(1-benzofuran-2-ylmethyl)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butylpiperazine-2-carboxamide

(2S)-4-(1-benzofuran-2-ylmethyl)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butylpiperazine-2-carboxamide

C39H48N4O5 (652.3625)


   

PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C35H57O9P (652.374)


   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0)

C35H57O9P (652.374)


   

PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C35H57O9P (652.374)


   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0)

C35H57O9P (652.374)


   

PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C35H57O9P (652.374)


   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0)

C35H57O9P (652.374)


   

PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C35H57O9P (652.374)


   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0)

C35H57O9P (652.374)


   

PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C35H57O9P (652.374)


   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0)

C35H57O9P (652.374)


   

Dgdg O-14:1_2:0

Dgdg O-14:1_2:0

C31H56O14 (652.367)


   

Dgdg O-13:1_3:0

Dgdg O-13:1_3:0

C31H56O14 (652.367)


   
   
   

PA 20:3/12:3;O

PA 20:3/12:3;O

C35H57O9P (652.374)


   
   

PEth 30:6;O

PEth 30:6;O

C35H57O9P (652.374)


   
   

ST 29:2;O5;GlcA

ST 29:2;O5;GlcA

C35H56O11 (652.3822)


   

ST 29:3;O6;Hex

ST 29:3;O6;Hex

C35H56O11 (652.3822)


   

n-(1-oxo-1-{[(8z,10z,16z)-3,15,24-trihydroxy-5,22-dimethoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20(24),21-octaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid

n-(1-oxo-1-{[(8z,10z,16z)-3,15,24-trihydroxy-5,22-dimethoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20(24),21-octaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid

C37H52N2O8 (652.3723)


   

(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl (1r,2r,4as,6as,6br,8ar,9r,10r,11r,12s,12ar,12bs,14bs)-1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl (1r,2r,4as,6as,6br,8ar,9r,10r,11r,12s,12ar,12bs,14bs)-1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C35H56O11 (652.3822)


   

3,4,5-trihydroxyoxan-2-yl 1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

3,4,5-trihydroxyoxan-2-yl 1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C35H56O11 (652.3822)


   

(2s)-2-({[(2s)-1-[(2s)-2-({[(2s)-1-[(2s)-2-{[(2s)-2-amino-1-hydroxy-3-methylbutylidene]amino}-4-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylbutanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)pentanedioic acid

(2s)-2-({[(2s)-1-[(2s)-2-({[(2s)-1-[(2s)-2-{[(2s)-2-amino-1-hydroxy-3-methylbutylidene]amino}-4-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylbutanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)pentanedioic acid

C31H52N6O9 (652.3796)


   

12β,21-dihydroxycimigenol3-o-α-l-arabinopyranoside

NA

C35H56O11 (652.3822)


{"Ingredient_id": "HBIN000742","Ingredient_name": "12\u03b2,21-dihydroxycimigenol3-o-\u03b1-l-arabinopyranoside","Alias": "NA","Ingredient_formula": "C35H56O11","Ingredient_Smile": "CC1(C2CCC3C4(C(C56C(C4(C(CC37C2(C7)CCC1OC8C(C(C(CO8)O)O)O)O)C)C(CC(O5)C(O6)C(C)(C)O)CO)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5789","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

2α, 3β, 23-trihydroxyurs-5, 12-dien-28-oic acid

NA

C35H56O11 (652.3822)


{"Ingredient_id": "HBIN005214","Ingredient_name": "2\u03b1, 3\u03b2, 23-trihydroxyurs-5, 12-dien-28-oic acid","Alias": "NA","Ingredient_formula": "C35H56O11","Ingredient_Smile": "CC1(C2CCC3C4(C(C56C(C4(C(CC37C2(C7)CCC1OC8C(C(C(CO8)O)O)O)O)C)C(CC(O5)C(O6)C(C)(C)O)CO)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42093","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

2-{[2,16-dihydroxy-19-(hydroxymethyl)-22-(2-hydroxypropan-2-yl)-3,8,8,17-tetramethyl-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxane-3,4,5-triol

2-{[2,16-dihydroxy-19-(hydroxymethyl)-22-(2-hydroxypropan-2-yl)-3,8,8,17-tetramethyl-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxane-3,4,5-triol

C35H56O11 (652.3822)


   

(5e,21z,31e)-12,25,28,30,35-pentahydroxy-6,22,32-trimethyl-9-(prop-1-en-2-yl)pentacyclo[16.15.1.1¹⁰,¹⁴.0²,¹⁶.0²⁴,²⁹]pentatriaconta-5,10(35),11,13,18(34),21,24,26,28,31-decaene-2-carbaldehyde

(5e,21z,31e)-12,25,28,30,35-pentahydroxy-6,22,32-trimethyl-9-(prop-1-en-2-yl)pentacyclo[16.15.1.1¹⁰,¹⁴.0²,¹⁶.0²⁴,²⁹]pentatriaconta-5,10(35),11,13,18(34),21,24,26,28,31-decaene-2-carbaldehyde

C42H52O6 (652.3764)


   

2,17,31,33,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

2,17,31,33,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

C42H52O6 (652.3764)


   

(2s,3e,6r,7r,10e,14r,21s,26z)-2,17,30,32,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

(2s,3e,6r,7r,10e,14r,21s,26z)-2,17,30,32,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

C42H52O6 (652.3764)


   

(1r,3as,9as,11as)-2,8-dihydroxy-1-[(2r)-2-hydroxy-6-methyl-3-oxoheptan-2-yl]-3a,6,6,11a-tetramethyl-7-{[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,9bh,11h-cyclopenta[a]phenanthren-10-one

(1r,3as,9as,11as)-2,8-dihydroxy-1-[(2r)-2-hydroxy-6-methyl-3-oxoheptan-2-yl]-3a,6,6,11a-tetramethyl-7-{[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,9bh,11h-cyclopenta[a]phenanthren-10-one

C35H56O11 (652.3822)


   

2-({[1-(2-{[(1-{2-[(2-amino-1-hydroxy-3-methylbutylidene)amino]-4-methylpentanoyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-3-methylbutanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)pentanedioic acid

2-({[1-(2-{[(1-{2-[(2-amino-1-hydroxy-3-methylbutylidene)amino]-4-methylpentanoyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-3-methylbutanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)pentanedioic acid

C31H52N6O9 (652.3796)


   

(2s,3r,4r,5r,6r)-2-{[(2r,3r,4r,6r)-6-{[(2s,3s,6s,8s,11r,14r,17r,18s,19s)-19-hydroxy-3,13,18-trimethyl-12,20-dioxahexacyclo[11.6.1.0²,¹¹.0³,⁸.0¹¹,¹⁷.0¹⁴,¹⁸]icosan-6-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-6-methyloxane-3,5-diol

(2s,3r,4r,5r,6r)-2-{[(2r,3r,4r,6r)-6-{[(2s,3s,6s,8s,11r,14r,17r,18s,19s)-19-hydroxy-3,13,18-trimethyl-12,20-dioxahexacyclo[11.6.1.0²,¹¹.0³,⁸.0¹¹,¹⁷.0¹⁴,¹⁸]icosan-6-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-6-methyloxane-3,5-diol

C35H56O11 (652.3822)


   

(2s,3e,6s,7s,10e,14r,21s,26z)-2,17,31,33,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

(2s,3e,6s,7s,10e,14r,21s,26z)-2,17,31,33,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

C42H52O6 (652.3764)


   

(2s,3r,4s,5s)-2-{[(1s,2r,3s,4r,7r,9s,12r,14r,16r,17r,18r,19r,21r,22s)-2,16-dihydroxy-19-(hydroxymethyl)-22-(2-hydroxypropan-2-yl)-3,8,8,17-tetramethyl-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxane-3,4,5-triol

(2s,3r,4s,5s)-2-{[(1s,2r,3s,4r,7r,9s,12r,14r,16r,17r,18r,19r,21r,22s)-2,16-dihydroxy-19-(hydroxymethyl)-22-(2-hydroxypropan-2-yl)-3,8,8,17-tetramethyl-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxane-3,4,5-triol

C35H56O11 (652.3822)


   

(2s,3e,6r,7s,10e,14s,21s,26z)-2,17,30,32,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

(2s,3e,6r,7s,10e,14s,21s,26z)-2,17,30,32,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

C42H52O6 (652.3764)